1020569-65-6

Basic information

• Product Name: ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate
• Synonyms: ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate;ethyl 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate;ETHYL 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)ISOXAZOLE-4-CARBOXYLATE(WXC09918)
• CAS NO: 1020569-65-6
• Molecular Formula: C₁₅H₁₃Cl₂NO₃
• Molecular Weight: 326.17462
• Mol File: 1020569-65-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 445.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.376±0.06 g/cm3(Predicted)
• PKA: -5.92±0.50(Predicted)
• CAS DataBase Reference: ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate(1020569-65-6)
• EPA Substance Registry System: ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate(1020569-65-6)

Safety Data

• Hazardous Substances Data: 1020569-65-6(Hazardous Substances Data)

Usage

General Description

Ethyl 3-(2,6-dichlorophenyl)-5-cyclopropylisoxazole-4-carboxylate, also known as Ioxapiprol, is a chemical compound that belongs to the class of isoxazoles. Ioxapiprol is a synthetic insecticide and acaricide that is used to control a wide range of pests, including mites, aphids, thrips, and whiteflies on various crops such as fruits, vegetables, and ornamental plants. It works by disrupting the nervous system of the pests, leading to paralysis and ultimately death. Ioxapiprol is typically applied as a foliar spray and has shown to be effective in controlling pest infestations while minimizing harm to non-target organisms and the environment. However, it is important to follow safety guidelines and regulations when using Ioxapiprol to minimize potential risks to human health and the environment.

Upstream product

• 3714-77-0 2,6-dichlorobenzaldoxime 
• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 

Downstream Products

• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1268245-10-8 (-)-3-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1268245-50-6 4-(chloromethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 1268245-14-2 4-((4-(2-(6-(1H-tetrazol-5-yl)pyridin-3-yl)cyclopropyl)-3-chlorophenoxy)methyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1268245-15-3 5-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)picolinic acid 
• 1245614-08-7 C₂₂H₁₇Cl₂F₃N₂O₄ 
• 1245614-10-1 C₂₀H₁₅Cl₂F₃N₂O₃ 
• 1245614-20-3 C₂₀H₁₃Cl₂F₃N₂O₃ 
• 1268245-17-5 3-(2-(6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)cyclopropyl)benzoic acid 
• 1268245-19-7 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)isooxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1268245-21-1 C₄H₁₁NO₃*C₂₉H₂₂Cl₃NO₄ 

Relevant articles and documents

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

The farnesoid X receptor (FXR) is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and other bile acid related diseases because it plays a critical role in fibrosis, inflammation and bile acid homeostasis. Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. However, the pruritus which was the main side effect of OCA limited its further applications in NASH. Although pruritus was also observed in the clinical trials of non-steroidal FXR agonists, the proportion of patients with pruritus was much smaller than that of OCA. Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether. Encouragingly, in the following biological tests, our target compounds 13j and 13z not only showed potent FXR agonistic activities in vitro, but also effectively promoted the expression of target genes in vivo. More importantly, in the pharmacokinetic experiments, compounds 13j and 13z displayed high liver/blood ratio characteristics which were helpful to reduce the potential side effects which were caused by prolonged systemic activation of FXR. In summary, our compounds were good choices for the development of non-steroidal FXR agonists and were deserved further investigation.

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor(FXR, NR1H4).